416
Participants
Start Date
September 1, 2020
Primary Completion Date
May 21, 2021
Study Completion Date
August 19, 2021
XAV-19
Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Placebo
Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
CHU Amiens Picardie, Amiens
CHU Angers, Angers
Hôpital Privé d'Antony, Antony
CH Avignon, Avignon
CH de la Côte Basque, Bayonne
APHP - Hôpital Avicennes, Bobigny
CHU Caen, Caen
CH Métropole Savoie, Chambéry
CH Colmar, Colmar
CH Sud Francilien, Corbeil-Essonnes
CHD Vendée, La Roche-sur-Yon
CH de La Rochelle, La Rochelle
CH Le Mans, Le Mans
CHRU Lille, Lille
CHU Limoges, Limoges
Hospices Civils Lyon, Lyon
CH de Mont de Marzan, Mont-de-Marsan
GHR Mulhouse Sud-Alsace, Mulhouse
CHU Nantes, Nantes
CHU Nice, Nice
CHU Nîmes, Nîmes
CHR Orléans La Source, Orléans
APHP - Hôpital Tenon, Paris
Hôpital Saint Antoine, Paris
CH René Dubos, Pontoise
CH Cornouaille, Quimper
CHU Reims, Reims
CHU Saint Etienne, Saint-Priest-en-Jarez
CHU Strasbourg, Strasbourg
Hôpital FOCH, Suresnes
CHRU Nancy, Vandœuvre-lès-Nancy
CH Bretagne Atlantique, Vannes
CHU Martinique, Fort-de-France
CHU La Réunion, Saint-Pierre
BPIfrance
OTHER
Xenothera SAS
INDUSTRY
Nantes University Hospital
OTHER